b*a
2 楼
rt,lg现在准备换个实验室,有几个实验室有意向,有的已经要了推荐信,有的最近会
电话联系。但基本都是外州的。
我们因为孩子要在8月出生,希望能在5月底之前搬过去,所以想知道是不是多数实验室
还需要去面试?一般从有意向到最好搞定offer(收到正式offer)要多久呢?时间是不
是有点紧张呢?
以前在国内找的时候不需要面试基本上3个月内搞定的,不知道在美国境内是不是能快
点。
多谢各位!!
电话联系。但基本都是外州的。
我们因为孩子要在8月出生,希望能在5月底之前搬过去,所以想知道是不是多数实验室
还需要去面试?一般从有意向到最好搞定offer(收到正式offer)要多久呢?时间是不
是有点紧张呢?
以前在国内找的时候不需要面试基本上3个月内搞定的,不知道在美国境内是不是能快
点。
多谢各位!!
g*y
3 楼
我们的工厂一直在为美国客户提供集成电路产品装配中使用的各种精密金属产品,但是
目前客户数量较少,如果有哪位朋友对这些客户有一定的联系,可以帮助我们做为一个代
理来和这些客户联系.
有兴趣请站内联系
目前客户数量较少,如果有哪位朋友对这些客户有一定的联系,可以帮助我们做为一个代
理来和这些客户联系.
有兴趣请站内联系
c*o
4 楼
【 以下文字转载自 Visa 讨论区 】
发信人: commando (卡曼多), 信区: Visa
标 题: H1-B transfer期间能回国吗?
发信站: BBS 未名空间站 (Wed May 13 16:14:07 2009), 转信
现在在employer A工作,打算9月1号去employer B工作。如果6月份B提交transfer pet
ition 后辞去在A的工作,能回国待到9月份再回来吗?
发信人: commando (卡曼多), 信区: Visa
标 题: H1-B transfer期间能回国吗?
发信站: BBS 未名空间站 (Wed May 13 16:14:07 2009), 转信
现在在employer A工作,打算9月1号去employer B工作。如果6月份B提交transfer pet
ition 后辞去在A的工作,能回国待到9月份再回来吗?
h*2
5 楼
bought a netbook, no cd
currently with ubuntu, how can i switch to XP?
Thank you!
currently with ubuntu, how can i switch to XP?
Thank you!
a*n
7 楼
多久能找到这个不好说。有的教授很拖拉,可能要了推荐信1个月才决定给不给面试,
面试也可能又安排在1个月后,然后又要一个月才能决定给不给offer。当然也有很快
就安排面试的。
国内找,不用去实验室,只要教授有1-2小时时间,不管他在什么地方都能面试。
美国找,飞过去面试首先要保证教授在实验室。很多教授超级忙,在实验室的时间1个
月可能就一周。所以不一定美国境内就比较快。
【在 b*******a 的大作中提到】
: rt,lg现在准备换个实验室,有几个实验室有意向,有的已经要了推荐信,有的最近会
: 电话联系。但基本都是外州的。
: 我们因为孩子要在8月出生,希望能在5月底之前搬过去,所以想知道是不是多数实验室
: 还需要去面试?一般从有意向到最好搞定offer(收到正式offer)要多久呢?时间是不
: 是有点紧张呢?
: 以前在国内找的时候不需要面试基本上3个月内搞定的,不知道在美国境内是不是能快
: 点。
: 多谢各位!!
面试也可能又安排在1个月后,然后又要一个月才能决定给不给offer。当然也有很快
就安排面试的。
国内找,不用去实验室,只要教授有1-2小时时间,不管他在什么地方都能面试。
美国找,飞过去面试首先要保证教授在实验室。很多教授超级忙,在实验室的时间1个
月可能就一周。所以不一定美国境内就比较快。
【在 b*******a 的大作中提到】
: rt,lg现在准备换个实验室,有几个实验室有意向,有的已经要了推荐信,有的最近会
: 电话联系。但基本都是外州的。
: 我们因为孩子要在8月出生,希望能在5月底之前搬过去,所以想知道是不是多数实验室
: 还需要去面试?一般从有意向到最好搞定offer(收到正式offer)要多久呢?时间是不
: 是有点紧张呢?
: 以前在国内找的时候不需要面试基本上3个月内搞定的,不知道在美国境内是不是能快
: 点。
: 多谢各位!!
n*y
8 楼
LZ自己就在LA为什么还需要其他代理?
f*o
15 楼
POSSIBLY EFFECTIVE
Age-related memory impairment. Taking ginkgo leaf extract orally seems to
improve cognitive function in some elderly people with mild to moderate age-
related memory or cognitive impairment. Ginkgo leaf extract might modestly
improve some measures of cognitive function, particularly short-term visual
memory and possibly speed of cognitive processing, in non-demented patients
with age-related memory impairment (5717,6216). But taking ginkgo leaf
extract does not improve memory in people over the age of 60 with normal
mental function (5718,8586,8587,8588).
Clinical research also shows that taking a standardized ginkgo leaf extract
(Thorne Research) 240 mg daily does not reduce the risk of developing age-
related cognitive impairment in elderly patients aged 85 years and older who
have normal cognitive function (16635).
Ginkgo has also been evaluated for prevention of dementia in patients with
existing age-related cognitive impairment. Epidemiologic research shows that
taking ginkgo is not associated with a decreased risk of developing
dementia in elderly patients with memory impairment; however, it might be
associated with a decreased risk of overall mortality (14812). A large-scale
clinical trial also shows that taking ginkgo extract 120 mg twice daily
does not reduce the risk of developing all-cause dementia or Alzheimer's
disease in elderly patients with mild cognitive impairment (16634).
Cognitive function. Taking ginkgo leaf extract orally seems to improve some
measures of cognitive function in healthy young to middle-aged people.
Ginkgo might modestly improve memory and speed of cognitive processing,
including increasing speed of performance on factors assessing attention in
people with no complaints of memory impairment (6214,6215,8236,8544,8588,
9759). Lower doses of 120-240 mg per day seem to be as effective or more
effective than higher doses up to 600 mg per day (6214,8236,8588). Some
evidence suggests a combination of Panax ginseng and ginkgo is effective for
enhancing memory and that the combination might be more effective than
either product alone (8591,9759).
Dementia. Some evidence shows that taking ginkgo leaf extract orally
modestly improves symptoms of Alzheimer's, vascular, or mixed dementias.
Studies lasting from 3 months to a year show that ginkgo leaf extract can
stabilize or improve some measures of cognitive function and social
functioning in patients with multiple types of dementia (1514,1515,2665,2666
,6222,6223,6224,6225,6490,11981,16636) (17191,17717). However, due to poor
study quality, there are concerns that some of the early ginkgo studies may
not be reliable. Although most clinical trials show benefit, there are some
conflicting findings suggesting inconsistent and unpredictable potential
benefits (5720,16636,16637).
There has been some debate about whether ginkgo is more effective in
dementia patients who have neuropsychiatric symptoms. Clinical research
shows that ginkgo is not more effective in patients with neuropsychiatric
symptoms compared to those without (17717).
Most clinical studies have not compared ginkgo to conventional drugs such as
the cholinesterase inhibitors. However, in a preliminary comparative trial,
a specific ginkgo leaf extract (EGb 761, Tanakan, Ipsen) 160 mg daily seems
to be comparable to donepezil 5 mg daily for mild to moderate Alzheimer's
dementia after 24 weeks of treatment (14499). Indirect comparisons suggest
that ginkgo might be less effective than the conventional drugs donepezil (
Aricept), tacrine (Cognex), and other cholinesterase inhibitors (6224,6490,
11981).
Ginkgo has also been evaluated for prevention of dementia. Epidemiologic
research shows that taking ginkgo is not associated with a decreased risk of
developing dementia in elderly patients with memory impairment; however, it
might be associated with a decreased risk of overall mortality (14812). A
large-scale clinical trial also shows that taking ginkgo extract 120 mg
twice daily does not reduce the risk of developing all-cause dementia or
Alzheimer's disease in elderly patients with normal cognitive function or in
those with mild cognitive impairment (16634).
Most of the clinical studies on the effectiveness of ginkgo leaf for
dementia have used the standardized extracts EGb 761 (Tanakan, Ipsen) and LI
1370 (Lichtwer Pharma). These two extracts are similar and prepared to
contain approximately 24% to 25% flavone glycosides and 6% terpene lactones.
Products with similar ingredients include Ginkai (Lichtwer Pharma), Ginkgo
5 (Pharmline), Ginkgold and Ginkgo (Nature's Way), and Quanterra Mental
Sharpness (Warner-Lambert).
Age-related memory impairment. Taking ginkgo leaf extract orally seems to
improve cognitive function in some elderly people with mild to moderate age-
related memory or cognitive impairment. Ginkgo leaf extract might modestly
improve some measures of cognitive function, particularly short-term visual
memory and possibly speed of cognitive processing, in non-demented patients
with age-related memory impairment (5717,6216). But taking ginkgo leaf
extract does not improve memory in people over the age of 60 with normal
mental function (5718,8586,8587,8588).
Clinical research also shows that taking a standardized ginkgo leaf extract
(Thorne Research) 240 mg daily does not reduce the risk of developing age-
related cognitive impairment in elderly patients aged 85 years and older who
have normal cognitive function (16635).
Ginkgo has also been evaluated for prevention of dementia in patients with
existing age-related cognitive impairment. Epidemiologic research shows that
taking ginkgo is not associated with a decreased risk of developing
dementia in elderly patients with memory impairment; however, it might be
associated with a decreased risk of overall mortality (14812). A large-scale
clinical trial also shows that taking ginkgo extract 120 mg twice daily
does not reduce the risk of developing all-cause dementia or Alzheimer's
disease in elderly patients with mild cognitive impairment (16634).
Cognitive function. Taking ginkgo leaf extract orally seems to improve some
measures of cognitive function in healthy young to middle-aged people.
Ginkgo might modestly improve memory and speed of cognitive processing,
including increasing speed of performance on factors assessing attention in
people with no complaints of memory impairment (6214,6215,8236,8544,8588,
9759). Lower doses of 120-240 mg per day seem to be as effective or more
effective than higher doses up to 600 mg per day (6214,8236,8588). Some
evidence suggests a combination of Panax ginseng and ginkgo is effective for
enhancing memory and that the combination might be more effective than
either product alone (8591,9759).
Dementia. Some evidence shows that taking ginkgo leaf extract orally
modestly improves symptoms of Alzheimer's, vascular, or mixed dementias.
Studies lasting from 3 months to a year show that ginkgo leaf extract can
stabilize or improve some measures of cognitive function and social
functioning in patients with multiple types of dementia (1514,1515,2665,2666
,6222,6223,6224,6225,6490,11981,16636) (17191,17717). However, due to poor
study quality, there are concerns that some of the early ginkgo studies may
not be reliable. Although most clinical trials show benefit, there are some
conflicting findings suggesting inconsistent and unpredictable potential
benefits (5720,16636,16637).
There has been some debate about whether ginkgo is more effective in
dementia patients who have neuropsychiatric symptoms. Clinical research
shows that ginkgo is not more effective in patients with neuropsychiatric
symptoms compared to those without (17717).
Most clinical studies have not compared ginkgo to conventional drugs such as
the cholinesterase inhibitors. However, in a preliminary comparative trial,
a specific ginkgo leaf extract (EGb 761, Tanakan, Ipsen) 160 mg daily seems
to be comparable to donepezil 5 mg daily for mild to moderate Alzheimer's
dementia after 24 weeks of treatment (14499). Indirect comparisons suggest
that ginkgo might be less effective than the conventional drugs donepezil (
Aricept), tacrine (Cognex), and other cholinesterase inhibitors (6224,6490,
11981).
Ginkgo has also been evaluated for prevention of dementia. Epidemiologic
research shows that taking ginkgo is not associated with a decreased risk of
developing dementia in elderly patients with memory impairment; however, it
might be associated with a decreased risk of overall mortality (14812). A
large-scale clinical trial also shows that taking ginkgo extract 120 mg
twice daily does not reduce the risk of developing all-cause dementia or
Alzheimer's disease in elderly patients with normal cognitive function or in
those with mild cognitive impairment (16634).
Most of the clinical studies on the effectiveness of ginkgo leaf for
dementia have used the standardized extracts EGb 761 (Tanakan, Ipsen) and LI
1370 (Lichtwer Pharma). These two extracts are similar and prepared to
contain approximately 24% to 25% flavone glycosides and 6% terpene lactones.
Products with similar ingredients include Ginkai (Lichtwer Pharma), Ginkgo
5 (Pharmline), Ginkgold and Ginkgo (Nature's Way), and Quanterra Mental
Sharpness (Warner-Lambert).
n*r
18 楼
踢馆的?
有包子的话就告诉你. 哈哈
有包子的话就告诉你. 哈哈
m*g
19 楼
基本上都是要面试的。
相关阅读
firefox 3.6 没话说了大侠讲讲system deployment tool 吧如何用文本编辑器打开一个man page?请推荐一个替代ultraedit的开源软件macbook pro怎么读ext3的硬盘? (转载)windows 下用emacs可以远程编辑linux的文件吗?装ubuntu 10.04的时候双系统下windows重装后无法进入linuxubuntu 10.04 太烂了,有没有办法恢复到9.10Ubuntu 怎么让命令行提示符现实部分当前路径 比如最后3层有人用过Sun Studio/Oracle Studio吗?有人试过wine一下cisco ipsec vpn client吗?Linux里如何用C查看某个程序已经运行?Linux Hot Girlfedroa's problemC/C++ programmer wanted (转载)KDE 4.5 发布了。。。hehe推荐xournal现在xp & ubuntu双系统,怎么装WIN7?跨平台IDE中哪个最好用?